MCID: SYS053
MIFTS: 23

Systemic Lupus Erythematosus 5

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus 5

MalaCards integrated aliases for Systemic Lupus Erythematosus 5:

Name: Systemic Lupus Erythematosus 5 54
Systemic Lupus Erythematosus, Susceptibility to, 5 13

Classifications:



External Ids:

OMIM 54 609903

Summaries for Systemic Lupus Erythematosus 5

MalaCards based summary : Systemic Lupus Erythematosus 5, also known as systemic lupus erythematosus, susceptibility to, 5, is related to systemic lupus erythematosus and thrombotic thrombocytopenic purpura. An important gene associated with Systemic Lupus Erythematosus 5 is SLEB5 (Systemic Lupus Erythematosus, Susceptibility To, 5). The drugs belimumab and beta-endorphin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, eye and testes.

Description from OMIM: 609903

Related Diseases for Systemic Lupus Erythematosus 5

Symptoms & Phenotypes for Systemic Lupus Erythematosus 5

Clinical features from OMIM:

609903

Drugs & Therapeutics for Systemic Lupus Erythematosus 5

Drugs for Systemic Lupus Erythematosus 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
belimumab Approved Phase 4,Phase 2,Phase 1 356547-88-1 5957 10451420
2 beta-endorphin Phase 4
3 Adrenocorticotropic Hormone Phase 4
4 Hormone Antagonists Phase 4,Phase 3,Phase 2
5 Hormones Phase 4,Phase 3,Phase 2
6 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
7 Estrogens Phase 4
8 Estrogens, Conjugated (USP) Phase 4
9 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
10 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 1
13 Melanocyte-Stimulating Hormones Phase 4
14 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
15 Antimalarials Phase 4,Phase 3,Phase 2
16 Autoantibodies Phase 4,Phase 2,Phase 3
17
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
18
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
19
Hydroxychloroquine Approved Phase 3,Phase 2 118-42-3 3652
20
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
21
Benzocaine Approved Phase 3,Phase 1 1994-09-7, 94-09-7 2337
22
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
23
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
24
Hydrocortisone Approved, Vet_approved Phase 3,Phase 1 50-23-7 5754 657311
25
Infliximab Approved Phase 2, Phase 3 170277-31-3
26 tannic acid Approved, Nutraceutical Phase 3,Phase 1
27 Atorvastatin Calcium Phase 2, Phase 3 134523-03-8
28 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2, Phase 3
29 Hypolipidemic Agents Phase 2, Phase 3
30 Anticholesteremic Agents Phase 2, Phase 3
31 Lipid Regulating Agents Phase 2, Phase 3
32 Antimetabolites Phase 2, Phase 3, Phase 1
33 Calcium, Dietary Phase 2, Phase 3,Early Phase 1
34 Prednisolone acetate Phase 3,Phase 2
35 Alkylating Agents Phase 3,Phase 2,Phase 1
36 glucocorticoids Phase 3,Phase 2
37 Methylprednisolone acetate Phase 3,Phase 2
38 Methylprednisolone Hemisuccinate Phase 3,Phase 2
39 Gastrointestinal Agents Phase 2, Phase 3
40 Neuroprotective Agents Phase 3,Phase 2
41 Heptavalent Pneumococcal Conjugate Vaccine Phase 2, Phase 3
42 Dermatologic Agents Phase 2, Phase 3
43 Vaccines Phase 2, Phase 3
44 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
45 Anti-Infective Agents Phase 3,Phase 2,Phase 1
46 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
47 Prednisolone hemisuccinate Phase 3,Phase 2
48 Prednisolone phosphate Phase 3,Phase 2
49 Antiemetics Phase 3,Phase 2
50 Protective Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 111)

id Name Status NCT ID Phase Drugs
1 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
2 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
3 Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Completed NCT01769937 Phase 4 H.P. Acthar Gel
4 A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT02953821 Phase 4 Repository corticotropin injection;Placebo gel
5 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
6 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Active, not recruiting NCT01753401 Phase 4 Acthar;Placebo for Acthar
7 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
8 Levothyroxine in Pregnant SLE Patients Withdrawn NCT01276782 Phase 4 Levothyroxine
9 An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus Unknown status NCT00432354 Phase 2, Phase 3 atorvastatin
10 On Open-Label Study in Participants With Systemic Lupus Erythematosus Completed NCT01488708 Phase 3 LY2127399;Placebo
11 Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus Completed NCT00611663 Phase 2, Phase 3
12 A Study of LY2127399 in Patients With Systemic Lupus Erythematosus Completed NCT01205438 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks
13 A Study of LY2127399 in Patients With Systemic Lupus Erythematosus Completed NCT01196091 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks
14 Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus Completed NCT01408576 Phase 3 Epratuzumab;Epratuzumab
15 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) Completed NCT01261793 Phase 3 Placebo;Epratuzumab;Epratuzumab
16 Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus Recruiting NCT02558517 Phase 3 prednisone discontinuation
17 Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus Recruiting NCT02794285 Phase 3 Placebo
18 A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus Active, not recruiting NCT02504645 Phase 3 IPP-201101;Placebo
19 Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Active, not recruiting NCT02446899 Phase 3 Placebo
20 TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) Terminated NCT00368264 Phase 2, Phase 3 infliximab;placebo
21 A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus Terminated NCT02041091 Phase 3 Tabalumab Auto-Injector;Tabalumab Prefilled Syringe
22 Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis Withdrawn NCT00539799 Phase 3 prednisolone;Placebo
23 Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis Withdrawn NCT00336414 Phase 3 cyclophosphamide-prednisone-azathioprine
24 Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus Completed NCT00076752 Phase 2 fludarabine phosphate;cyclophosphamide;methylprednisolone;Diphenhydramine;Mesna
25 A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector Completed NCT02124798 Phase 2
26 Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus Completed NCT00556192 Phase 2 rituximab
27 Triptorelin for Ovary Protection in Childhood Onset Lupus Completed NCT00124514 Phase 2 Triptorelin pamoate
28 A Trial of Rosuvastatin in Systemic Lupus Erythematosus Completed NCT01170585 Phase 2 Rosuvastatin;Placebo
29 Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study Completed NCT00976300 Phase 2 Cyclosporine A;Cyclophosphamide
30 Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Completed NCT00660881 Phase 2
31 A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus Completed NCT00657189 Phase 2 MEDI-545;MEDI-545;MEDI-545;MEDI-545;Placebo
32 Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease Completed NCT00624351 Phase 2
33 PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus Completed NCT01162681 Phase 2 A-623;A-623;A-623
34 Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone Completed NCT00119678 Phase 2 Abatacept;Placebo;Prednisone;Abatacept
35 A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus. Completed NCT01031836 Phase 2 MEDI-545;MEDI-545;MEDI-545;MEDI-545;MEDI-545;MEDI-545 600
36 Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus Completed NCT01405196 Phase 2
37 Improving Quality of Life for African American Female Adolescents With Lupus Completed NCT00068874 Phase 2
38 Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous Recruiting NCT02320357 Phase 1, Phase 2 Treatment by clopidogrel
39 Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus Recruiting NCT03288324 Phase 1, Phase 2 Tofacitinib
40 Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches Recruiting NCT02270957 Phase 2
41 Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE) Recruiting NCT01946880 Phase 2 Mycophenolate Mofetil;Hydroxychloroquine or Chloroquine;Prednisone
42 Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Recruiting NCT02847598 Phase 2 BIIB059;Placebo
43 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Recruiting NCT01988506 Phase 2 Interleukin 2
44 A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE) Recruiting NCT02975336 Phase 2 Placebo;M2951;M2951;M2951
45 A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE) Active, not recruiting NCT02708095 Phase 2 Baricitinib;Placebo
46 Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy Active, not recruiting NCT01649765 Phase 2 belimumab 10mg/kg
47 Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus Active, not recruiting NCT02265744 Phase 2 BMS-931699;Placebo matching BMS-931699
48 A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus Active, not recruiting NCT02437890 Phase 2
49 Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Patients Who Participated in ADDRESS II) Active, not recruiting NCT02070978 Phase 2 Atacicept 75 mg;Atacicept 150 mg
50 JBT-101 in Systemic Lupus Erythematosus (SLE) Not yet recruiting NCT03093402 Phase 2 JBT-101;Placebo

Search NIH Clinical Center for Systemic Lupus Erythematosus 5

Genetic Tests for Systemic Lupus Erythematosus 5

Anatomical Context for Systemic Lupus Erythematosus 5

MalaCards organs/tissues related to Systemic Lupus Erythematosus 5:

39
Endothelial, Eye, Testes, Heart, Monocytes, T Cells, B Cells

Publications for Systemic Lupus Erythematosus 5

Articles related to Systemic Lupus Erythematosus 5:

id Title Authors Year
1
Development of systemic lupus erythematosus 5 years after onset of thrombotic thrombocytopenic purpura. ( 28707764 )
2017

Variations for Systemic Lupus Erythematosus 5

Expression for Systemic Lupus Erythematosus 5

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 5.

Pathways for Systemic Lupus Erythematosus 5

GO Terms for Systemic Lupus Erythematosus 5

Sources for Systemic Lupus Erythematosus 5

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....